The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Nanotechnology in vaccine delivery
Open accessAbstract
With very few adjuvants currently being used in marketed human vaccines, a critical need exists for novel immunopotentiators and delivery vehicles capable of eliciting humoral, cellular and mucosal immunity. Such crucial vaccine components could facilitate the development of novel vaccines for viral and parasitic infections, such as hepatitis, HIV, malaria, cancer, etc. In this review, we discuss clinical trial results for various vaccine adjuvants and delivery vehicles being developed that are approximately nanoscale (< 1000 nm) in size. Humoral immune responses have been observed for most adjuvants and delivery platforms while only viral vectors, ISCOMs and Montanide™ ISA 51 and 720 have shown cytotoxic T cell responses in the clinic. MF59 and MPL® have elicited Th1 responses, and virus-like particles, non-degradable nanoparticles and liposomes have also generated cellular immunity. Such vaccine components have also been evaluated for alternative routes of administration with clinical successes reported for intranasal delivery of viral vectors and proteosomes and oral delivery of a VLP vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
(2013) · Pediatrics · doi:10.1542/peds.2013-2511 · Cited by 1,845
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Synthetic DNA delivery systems
Luo, D., & Saltzman, W. M. (2000) · Nature Biotechnology · doi:10.1038/71889 · Cited by 1,626
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
(1988) · World Health Organization eBooks · Cited by 1,574
Elwood, J. M. (1989) · Journal of Epidemiology and Community Health · doi:10.1136/jech.43.1.92 · Cited by 1,412
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.
Fynan, E. F., Webster, R. G., Fuller, D. H., Haynes, J. R., Santoro, J. C., & Robinson, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11478 · Cited by 1,115
Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of Causality
Bosch, F. X., & de Sanjose, S. (2003) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003479 · Cited by 826
Human hepatitis B vaccine from recombinant yeast
McAleer, W. J., Buynak, E. B., Maigetter, R. Z., Wampler, D. E., Miller, W. J., & Hilleman, M. R. (1984) · Nature · doi:10.1038/307178a0 · Cited by 739
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z.-Y., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 663
Parren, P. W. H. I., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P., & Burton, D. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.17.8340-8347.2001 · Cited by 662
DNA-based therapeutics and DNA delivery systems: A comprehensive review
Patil, S. D., Rhodes, D. G., & Burgess, D. J. (2005) · The AAPS Journal · doi:10.1208/aapsj070109 · Cited by 630
Immunogenicity and protective efficacy of a tuberculosis DNA vaccine
Huygen, K., Content, J., Denis, O., Montgomery, D. L., Yawman, A. M., Randall Deck, R., DeWitt, C. M., Orme, I. M., Baldwin, S., D'Souza, C., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-893 · Cited by 629
Aluminum compounds as vaccine adjuvants
Gupta, R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00008-8 · Cited by 623
In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment.
Yang, N. S., Burkholder, J., Roberts, B., Martinell, B., & McCabe, D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.24.9568 · Cited by 600
Vaccines: past, present and future
Plotkin, S. A. (2005) · Nature Medicine · doi:10.1038/nm1209 · Cited by 592
Virus-like particles: Passport to immune recognition
Grgacic, E. V. L., & Anderson, D. A. (2006) · Methods · doi:10.1016/j.ymeth.2006.07.018 · Cited by 582
McConkey, S. J., Reece, W. H. H., Moorthy, V. S., Webster, D., Dunachie, S., Butcher, G., Vuola, J. M., Blanchard, T. J., Gothard, P., Watkins, K., et al. (2003) · Nature Medicine · doi:10.1038/nm881 · Cited by 553
Oka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O. A., Oji, Y., Kawakami, M., Ikegame, K., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405884101 · Cited by 531
Aluminium compounds for use in vaccines
Lindblad, E. B. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01286.x · Cited by 488
JIANG, W., GUPTA, R., DESHPANDE, M., & SCHWENDEMAN, S. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.09.003 · Cited by 478
Vaccine design : the subunit and adjuvant approach
Powell, M. F., Newman, M. J., & Burdman, J. R. (1995) · Plenum Press eBooks · Cited by 451
Davis, I. D., Chen, W., Jackson, H., Parente, P., Shackleton, M., Hopkins, W., Chen, Q., Dimopoulos, N., Luke, T., Murphy, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403572101 · Cited by 440
Akiyoshi, K., Kobayashi, S., Shichibe, S., Mix, D., Baudys, M., Wan Kim, S., & Sunamoto, J. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00017-0 · Cited by 437
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
Butts, C., Murray, N., Maksymiuk, A., Goss, G., Marshall, E., Soulières, D., Cormier, Y., Ellis, P., Price, A., Sawhney, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.011 · Cited by 428
Toxicological Hazards of Inhaled Nanoparticles—Potential Implications for Drug Delivery
Borm, P. J. A., & Kreyling, W. (2004) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2004.081 · Cited by 419
Eldridge, J. H., Staas, J. K., Meulbroek, J. A., Tice, T. R., & Gilley, R. M. (1991) · Infection and Immunity · doi:10.1128/iai.59.9.2978-2986.1991 · Cited by 368
Gherardi, R. K. (2001) · Brain · doi:10.1093/brain/124.9.1821 · Cited by 361
STUDIES ON THE O ANTIGEN OF SALMONELLA TYPHOSA
Johnson, A. G., Gaines, S., & Landy, M. (1956) · The Journal of Experimental Medicine · doi:10.1084/jem.103.2.225 · Cited by 358
Mechanisms of stimulation of the immune response by aluminum adjuvants
HogenEsch, H. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00169-x · Cited by 354
Liposomes as carriers of antigens and adjuvants
Alving, C. R. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90120-5 · Cited by 344
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333
Adjuvant Properties of Aluminum and Calcium Compounds
Gupta, R. K., Rost, B. E., Relyveld, E., & Siber, G. R. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_8 · Cited by 330
Catanzaro, A. T., Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/509258 · Cited by 321
(2005) · PsycEXTRA Dataset · doi:10.1037/e548762006-001 · Cited by 311
Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines
Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S., & Ganne, V (2002) · Expert Review of Vaccines · doi:10.1586/14760584.1.1.111 · Cited by 308
Hanke, T., Samuel, R. V., Blanchard, T. J., Neumann, V. C., Allen, T. M., Boyson, J. E., Sharpe, S. A., Cook, N., Smith, G. L., Watkins, D. I., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7524-7532.1999 · Cited by 304
Kamath, A. T., Feng, C. G., Macdonald, M., Briscoe, H., & Britton, W. J. (1999) · Infection and Immunity · doi:10.1128/.67.4.1702-1707.1999 · Cited by 301
Huleatt, J. W., Jacobs, A. R., Tang, J., Desai, P., Kopp, E. B., Huang, Y., Song, L., Nakaar, V., & Powell, T. J. (2007) · Vaccine · doi:10.1016/j.vaccine.2006.08.013 · Cited by 299
MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines
Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., & Van Nest, G. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_10 · Cited by 298
Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.
Ulrich, J. T., & Myers, K. R. (1995) · PubMed · Cited by 278
Biodegradable microparticles as controlled release antigen delivery systems.
O’Hagan, D. T., Rahman, D., McGee, J. P., Jeffery, H., Davies, M. C., Williams, P. M., Davis, S. S., & Challacombe, S. (1991) · PubMed Central · Cited by 270
Guirakhoo, F., Pugachev, K., Zhang, Z., Myers, G., Levenbook, I., Draper, K., Lang, J., Ocran, S., Mitchell, F., Parsons, M., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4761-4775.2004 · Cited by 253
The virosome concept for influenza vaccines
Huckriede, A., Bungener, L., Stegmann, T., Daemen, T., Medema, J., Palache, A. M., & Wilschut, J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.026 · Cited by 250
Elamanchili, P., Diwan, M., Cao, M., & Samuel, J. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.12.032 · Cited by 246
Preparation of coated nanoparticles for a new mucosal vaccine delivery system
Borges, O., Borchard, G., Verhoef, J. C., de Sousa, A., & Junginger, H. E. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.04.037 · Cited by 240
Gallichan, W. S., & Rosenthal, K. L. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1879 · Cited by 238
Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers
Tacket, C. O., Sztein, M. B., Losonsky, G. A., Wasserman, S. S., & Estes, M. K. (2003) · Clinical Immunology · doi:10.1016/s1521-6616(03)00120-7 · Cited by 238
Nanoparticulate Systems for Nasal Delivery of Drugs: A Real Improvement over Simple Systems?
Illum, L. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20718 · Cited by 237
Goonetilleke, N., Moore, S., Dally, L., Winstone, N., Cebere, I., Mahmoud, A., Pinheiro, S., Gillespie, G., Brown, D., Loach, V., et al. (2006) · Journal of Virology · doi:10.1128/jvi.80.10.4717-4728.2006 · Cited by 236
Mitchell, M. S., Kan‐Mitchell, J., Kempf, R. A., Harel, W., Shau, H., & Lind, S. (1988) · PubMed · Cited by 236
McShane, H., Brookes, R., Gilbert, S. C., & Hill, A. V. S. (2001) · Infection and Immunity · doi:10.1128/iai.69.2.681-686.2001 · Cited by 231
A short history of vaccination
Plotkin, S. L., & Plotkin, S. A. (2013) · Vaccines · doi:10.1016/b978-1-4557-0090-5.00017-3 · Cited by 222
Monophosphoryl Lipid A as an Adjuvant: Past Experiences and New Directions
Ulrich, J. T., & Myers, K. R. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_21 · Cited by 222
Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans
Van Kampen, K. R., Shi, Z., Gao, P., Zhang, J., Foster, K. W., Chen, D.-T., Marks, D., Elmets, C. A., & Tang, D.-C. C. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.07.043 · Cited by 220
A Compendium of Vaccine Adjuvants and Excipients
Vogel, F. R., & Powell, M. F. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_7 · Cited by 217
Nishikawa, T., Akiyoshi, K., & Sunamoto, J. (1996) · Journal of the American Chemical Society · doi:10.1021/ja953843c · Cited by 215
Microparticles as vaccine adjuvants and delivery systems
O’Hagan, D. T., & Singh, M. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.269 · Cited by 214
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults
Kündig, T. M., Senti, G., Schnetzler, G., Wolf, C., Prinz Vavricka, B. M., Fulurija, A., Hennecke, F., Sladko, K., Jennings, G. T., & Bachmann, M. F. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.040 · Cited by 199
Jones, L. S., Peek, L. J., Power, J., Markham, A., Yazzie, B., & Middaugh, C. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500687200 · Cited by 197
Self-citationGlenny, A. T., Buttle, G. A. H., & Stevens, M. F. (1931) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700340214 · Cited by 192
ISCOMs and other saponin based adjuvants
Barr, I. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00013-1 · Cited by 189
Dendritic Cells Internalize Vaccine Adjuvant after Intramuscular Injection
Dupuis, M., Murphy, T. J., Higgins, D., Ugozzoli, M., van Nest, G., Ott, G., & McDonald, D. M. (1998) · Cellular Immunology · doi:10.1006/cimm.1998.1283 · Cited by 185
MacLean, G. D., Reddish, M. A., Koganty, R. R., Wong, T. C., Gandhi, S. S., Smolenski, M., Samuel, J., Nabholtz, J. M., & Longenecker, B. M. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01740902 · Cited by 184
Inflexal®V a trivalent virosome subunit influenza vaccine: production
Mischler, R., & Metcalfe, I. C. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00512-1 · Cited by 183
Jung, T., Kamm, W., Breitenbach, A., Hungerer, K.-D., Hundt, E., & Kissel, T. (2001) · Pharmaceutical Research · doi:10.1023/a:1011063232257 · Cited by 177
A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy
Langenberg, A. G. M., Burke, R. L., Adair, S. F., Sekulovich, R., Tigges, M., Dekker, C. L., & Corey, L. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-12-199506150-00001 · Cited by 177
FRAZER, I., QUINN, M., NICKLIN, J., TAN, J., PERRIN, L., NG, P., OCONNOR, V, WHITE, O., WENDT, N., & MARTIN, J. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.05.013 · Cited by 176
Kim, T. W., Lee, J. H., Hung, C.-F., Peng, S., Roden, R., Wang, M.-C., Viscidi, R., Tsai, Y.-C., He, L., Chen, P.-J., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4638-4645.2004 · Cited by 173
Microparticle-based technologies for vaccines
O’Hagan, D. T., Singh, M., & Ulmer, J. B. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.017 · Cited by 172
Adenovirus Vector-Based Vaccines for Human Immunodeficiency Virus Type 1
Barouch, D. H., & Nabel, G. J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.149 · Cited by 168
Monophosphoryl Lipid A (MPL) Formulations for the Next Generation of Vaccines
Baldridge, J. R., & Crane, R. T. (1999) · Methods · doi:10.1006/meth.1999.0834 · Cited by 168
Audran, R., Peter, K., Dannull, J., Men, Y., Scandella, E., Groettrup, M., Gander, B., & Corradin, G. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00521-2 · Cited by 168
Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases
FULLER, D. H., Loudon, P. T., & Schmaljohn, C. S. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.022 · Cited by 155
Controlled release microparticles for vaccine development
O’Hagan, D. T., Jeffery, H., Roberts, M. J. J., McGee, J. P., & Davis, S. S. (1991) · Vaccine · doi:10.1016/0264-410x(91)90295-h · Cited by 149
Nakanishi, T., Kunisawa, J., Hayashi, A., Tsutsumi, Y. M., Kubo, K., Nakagawa, S., Nakanishi, M., Tanaka, K., & Mayumi, T. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00097-8 · Cited by 149
Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations
Atmar, R. L., Keitel, W., Patel, S. M., Katz, J. M., She, D., Sahly, H. M. E., Pompey, J. M., Cate, T. R., & Couch, R. B. (2006) · Clinical Infectious Diseases · doi:10.1086/508174 · Cited by 148
Pialoux, G., Excler, J., Rivière, Y., Gonzalez-Canali, G., FEUILLIE, V., Coulaud, P., Gluckman, J. C., Matthews, T. J., Meignier, B., Kiény, M.-P., et al. (1995) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1995.11.373 · Cited by 147
Berencsi, K., Gyulai, Z., Gönczöl, É., Pincus, S. E., Cox, W. I., Michelson, S., Kari, L., Méric, C., Cadoz, M., Zahradnik, J. M., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/319680 · Cited by 146
Saul, A. J., Lawrence, G., Smillie, A., Rzepczyk, C. M., Reed, C., Taylor, D. F., Anderson, K., Stowers, A. W., Kemp, R. J., Allworth, A. M., et al. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00175-9 · Cited by 140
Lawrence, G., Cheng, Q., Reed, C., Taylor, D. F., Stowers, A. W., Cloonan, N., Rzepczyk, C. M., Smillie, A., Anderson, K., Pombo, D., et al. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00444-2 · Cited by 139
Goto, N., Kato, H., Maeyama, J., Shibano, M., Saito, T., Yamaguchi, J., & Yoshihara, S. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00054-6 · Cited by 136
Rimmelzwaan, G. F., Nieuwkoop, N., Brandenburg, A., Sutter, G., Beyer, W. E., Maher, D., Bates, J., & Osterhaus, A. D. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00310-8 · Cited by 136
Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria
Moore, A., & Hill, A. V. S. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00138.x · Cited by 134
Shouval, D., Ilan, Y., Adler, R., Deepen, R., Panet, A., Even-Chen, Z., Gorecki, M., & Gerlich, W. H. (1994) · Vaccine · doi:10.1016/0264-410x(94)90155-4 · Cited by 133
Gasparini, R., Pozzi, T., Montomoli, E., Fragapane, E., Senatore, F., Minutello, M., & Podda, A. (2001) · European Journal of Epidemiology · doi:10.1023/a:1017919305501 · Cited by 129
Biopharmaceuticals: Biochemistry and Biotechnology
Walsh, G. (1998) · Thammasat University Digital Collections · Cited by 129
Chianese‐Bullock, K. A., Pressley, J., Garbee, C. F., Hibbitts, S., Murphy, C., Yamshchikov, G. V., Petroni, G. R., Bissonette, E. A., Neese, P. Y., Grosh, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.3080 · Cited by 126
Frost, L., Johansen, P., Pedersen, S., Veien, N. K., AabelØstergaard, P., & Nielsen, M. H. (1985) · Allergy · doi:10.1111/j.1398-9995.1985.tb00249.x · Cited by 124
Lopez, J. A., Weilenman, C., Audran, R., et al. (2001) · IRIS · Cited by 122
MacLean, G. D., Bowen-Yacyshyn, M. B., Samuel, J., Meikle, A., Stuart, G. C. E., Nation, J. G., Poppema, S., Jerry, M., Koganty, R. R., Wong, T. C., et al. (1992) · Journal of Immunotherapy · doi:10.1097/00002371-199205000-00008 · Cited by 121
Hanke, T., McMichael, A. J., & Dorrell, L. (2006) · Journal of General Virology · doi:10.1099/vir.0.82493-0 · Cited by 119
Lipid based particulate formulations for the delivery of antigen
Copland, M. J., Rades, T., Davies, N. M., & Baird, M. A. (2005) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01315.x · Cited by 118
Fries, L. F., Montemarano, A. D., Mallett, C. P., Taylor, D. N., Hale, T. L., & Lowell, G. H. (2001) · Infection and Immunity · doi:10.1128/iai.69.7.4545-4553.2001 · Cited by 110
Ennis, F. A., Cruz, J., Jameson, J., Klein, M. H., Burt, D. S., & Thipphawong, J. (1999) · Virology · doi:10.1006/viro.1999.9765 · Cited by 109
López, J. A., Weilenman, C., Audran, R., Roggero, M. A., Bonelo, A., Tiercy, J., Spertini, F., & Corradin, G. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200107)31:7<1989::aid-immu1989>3.0.co;2-m · Cited by 109
Ikuta, Y., Katayama, N., Wang, L., Okugawa, T., Takahashi, Y., Schmitt, M. W., Xiaogang, G., Watanabe, M., Akiyoshi, K., Nakamura, H., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3717 · Cited by 108
Oliveira, G. A., Wetzel, K., Calvo‐Calle, J. M., Nussenzweig, R. S., Schmidt, A., Birkett, A. J., Dubovsky, F., Tierney, E. L., Gleiter, C. H., Boehmer, G., et al. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3587-3597.2005 · Cited by 106
Heineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D., Eiden, J., Nest, G. A. V., & Hsu, H. H. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00088-2 · Cited by 103
Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720
Lawrence, G., Saul, A. J., Giddy, A., Kemp, R. J., & Pye, D. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00150-8 · Cited by 102
Genton, B., Al-Yaman, F. M., Anders, R. F., Saul, A. J., Brown, G., Pye, D., Irving, D. O., Briggs, W. R. S., Mai, A., Ginny, M., et al. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00036-0 · Cited by 99
Miles, A. P., McClellan, H., Rausch, K. M., Zhu, D., Whitmore, M. D., Singh, S. P., Martin, L. B., Wu, Y., Giersing, B. K., Stowers, A. W., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.08.049 · Cited by 99
Nardin, E. H., Oliveira, G. A., Calvo‐Calle, J. M., Wetzel, K., Maier, C., Birkett, A. J., Sarpotdar, P. P., Corado, M. L., Thornton, G. B., & Schmidt, A. (2004) · Infection and Immunity · doi:10.1128/iai.72.11.6519-6527.2004 · Cited by 99
Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers
Mitchell, D. K., Holmes, S. J., BURKE, R. L., et al. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200202000-00009 · Cited by 98
Vaccine technologies: view to the future
Rabinovich, N. R., McInnes, P., Klein, D. L., & Hall, B. (1994) · Science · doi:10.1126/science.7521064 · Cited by 98
Men, Y., Tamber, H., Audran, R., Gander, B. A., & Corradin, G. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00047-9 · Cited by 97
Antiviral Cytotoxic T Lymphocyte Induction and Vaccination
Rouse, B. T., Norley, S., & Martin, S. J. (1988) · Clinical Infectious Diseases · doi:10.1093/clinids/10.1.16 · Cited by 97
Guan, H. H., Budzynski, W. A., Koganty, R. R., Krantz, M. J., Reddish, M. A., Rogers, J. A., Longenecker, B. M., & Samuel, J. (1998) · Bioconjugate Chemistry · doi:10.1021/bc970183n · Cited by 96
Moorthy, V. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00771-5 · Cited by 93
A Practical Approach to the use of Nanoparticles for Vaccine Delivery
Wendorf, J. R., Singh, M., Chesko, J., Kazzaz, J., Soewanan, E., Ugozzoli, M., & O’Hagan, D. T. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20728 · Cited by 91
Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses
Lutsiak, M. E. C., Kwon, G. S., & Samuel, J. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.6.0004 · Cited by 89
Recombinant viral vectors: Cancer vaccines
Harrop, R., John, J., & Carroll, M. W. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.005 · Cited by 88
Boyce, T. G., Hsu, H. H., Sannella, E. C., Coleman-Dockery, S. D., Baylis, E. F., Zhu, Y., Barchfeld, G. L., DiFrancesco, A., Paranandi, M., Culley, B. S., et al. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00171-7 · Cited by 81
Chemical Structure and Biologic Activity of Bacterial and Synthetic Lipid A
Rietschel, E., Brade, L., Brandenburg, K., Flad, H., de Jong-Leuveninck, J., Kawahara, K., Lindner, B., Loppnow, H., Lüderitz, T., Schade, U. F., et al. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.supplement_5.s527 · Cited by 81
Auger, F., Gendron, M., Chamot, C., Marano, F., & Dazy, A. C. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.03.002 · Cited by 76
Thapar, M., Parr, E. L., Bozzola, J. J., & Parr, M. B. (1991) · Vaccine · doi:10.1016/0264-410x(91)90269-c · Cited by 75
Certification of polio eradication: process and lessons learned.
Smith, J., Leke, R., Adams, A. I., & Tangermann, R. H. (2004) · Europe PMC (PubMed Central) · Cited by 75
Viral vectors for malaria vaccine development
Li, S., Locke, E., Bruder, J. T., Clarke, D. K., Doolan, D. L., Havenga, M. J. E., Hill, A. V. S., Liljeström, P., Monath, T. P. C., Naim, H. Y., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.07.035 · Cited by 73
Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice
Jin, H., Xiao, C., Chen, Z., Kang, Y., Ma, Y., Zhu, K., Xie, Q., Tu, Y.-X., Yu, Y., & Wang, B. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.048 · Cited by 69
Yap, I., Guan, R., & Chan, S. H. (1992) · Vaccine · doi:10.1016/0264-410x(92)90391-v · Cited by 69
Liposomal Vaccines: Clinical Status and Immunological Presentation for Humoral and Cellular Immunity
Alving, C. R. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44447.x · Cited by 67
The prime-boost concept applied to HIV preventive vaccines.
Jl, E., & Plotkin, S. A. (1997) · PubMed · Cited by 67
Influenza virosomes as an efficient system for adjuvanted vaccine delivery
Glück, R., Moser, C., & Metcalfe, I. C. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1139 · Cited by 63
Uptake and adjuvant activity of orally delivered saponin and ISCOM? vaccines
Sjölander, A. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00046-5 · Cited by 60
Martin, S. J., Vyakarnam, A., CHEINGSONG-POPOV, R., Callow, D., Jones, K. L., Senior, J. M., Adams, S. E., Kingsman, A. J., Matear, P. M., & Gotch, F. (1993) · PubMed · Cited by 60
McCormack, S., Tilzey, A., Carmichael, A. J., Gotch, F., Kepple, J., Newberry, A. M., Jones, G. J., Lister, S. G., Beddows, S. A., CHEINGSONG-POPOV, R., et al. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00388-6 · Cited by 58
Dorrell, L., Williams, P., Suttill, A., Brown, D., Roberts, J., Conlon, C. P., Hanke, T., & McMichael, A. J. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.005 · Cited by 57
Clinical experience with inactivated, virosomal influenza vaccine
de Bruijn, I. A., Nauta, J. J. P., Cramer, W., Gerez, L., & Palache, A. M. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.020 · Cited by 53
Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma
Hersey, P., Menzies, S. W., Coventry, B. J., Nguyen, T., Farrelly, M. L., Collins, S., Hirst, D., & Johnson, H. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0587-8 · Cited by 52
Glück, R. (1992) · Vaccine · doi:10.1016/0264-410x(92)90325-e · Cited by 52
Protollin™: a novel adjuvant for intranasal vaccines
Jones, T., Cyr, S. L., Allard, F., Bellerose, N., Lowell, G. H., & Burt, D. S. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.035 · Cited by 52
Langley, J. M., Halperin, S. A., McNeil, S., SMITH, B., JONES, T., Burt, D. S., Mallett, C. P., Lowell, G. H., & FRIES, L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.09.056 · Cited by 46
Kim, H., Tahara, K., Maxwell, J. A., Lalonde, R., Fukuiwa, T., Fujihashi, K., Kampen, K. R. V., Kong, F.-K., Tang, D.-C. C., & Fukuchi, K. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.993 · Cited by 45
Duncan, G., Jess, T. J., Mohamed, F., Price, N. C., Kelly, S. M., & van der Walle, C. F. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.007 · Cited by 43
Raghuvanshi, R. J. (2001) · Journal of Microencapsulation · doi:10.1080/02652040110055261 · Cited by 38
Garçon, N., Mechelen, M. V., & Wettendorff, M. A. (2006) · Elsevier eBooks · doi:10.1016/b978-012088403-2/50011-3 · Cited by 35
MF59: a safe and potent adjuvant for human use
Podda, A., Giudice, G. D., & O’Hagan, D. T. (2006) · Elsevier eBooks · doi:10.1016/b978-012088403-2/50010-1 · Cited by 31
Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases
Bricks, L. F., & Berezin, E. N. (2006) · Jornal de Pediatria · doi:10.2223/jped.1475 · Cited by 31
Cyr, S. L., Jones, T., Stoica-Popescu, I., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.037 · Cited by 27
Clinical evaluation of adjuvants
Simon, J. K., & Edelman, R. (2006) · Elsevier eBooks · doi:10.1016/b978-012088403-2/50019-8 · Cited by 18
Microparticles as vaccine delivery systems
O’Hagan, D. T. (2006) · Elsevier eBooks · doi:10.1016/b978-012088403-2/50009-5 · Cited by 14
Toll-like receptor 4 agonists as vaccine adjuvants
Persing, D. H., McGowan, P., Evans, J. T., Cuff, C. F., Mossman, S. P., Johnson, D. A., & Baldridge, J. R. (2006) · Elsevier eBooks · doi:10.1016/b978-012088403-2/50007-1 · Cited by 6
Cited by
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,864
Nanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
Programming the magnitude and persistence of antibody responses with innate immunity
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 975
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Minireview: Nanoparticles and the Immune System
Zolnik, B. S., González-Fernández, A., Sadrieh, N., & Dobrovolskaia, M. A. (2010) · Endocrinology · doi:10.1210/en.2009-1082 · Cited by 914
Metadata
- Authors
- Peek, L. J., Middaugh, C. R., & Berkland, C.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 60
- Issue
- 8
- Pages
- 915-928
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2001863331
- Cited by
- 562
- References
- 145
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.